Brain imaging AI start-up Neurophet raises $15M to better direct Alzheimer ’s treatments, lower ARIA side-effects

Korean AI startups Allganize, Neurophet raise over $35 mn (The Korea Economic Daily): Founded in 2016, the company plans to next year roll out its new AI analysis program that can detect side effects of Alzheimer’s disease treatments with a microhemorrhage diagnosis. The Korean AI startup is famous for its flagship AI analysis technologies, Neurophet AQUA, which is a brain MRI analysis technology, and Neurophet SCALE PET, an AI-based positron emission tomography (PET) image analysis program. It plans to go public in Korea next year, said Neurophet CEO Bin Joon-gil, adding that it is currently working with its underwriter Mirae Asset Securities for the IPO. The Announcement: Neurophet secures 20 billion in Series C funding to launch AI dementia treatment solution (Korea Biomedical Review): Alzheimer’s drugs such as lecanemab and donanemab, being developed and launched by global pharmaceutical companies, are anti-amyloid antibody treatments that aim to remove amyloid beta … Amyloid-PET imaging is required before prescribing treatment to determine whether amyloid beta is deposited in the cerebral cortex and whether it decreases afterward. Neurophet has developed Neurophet SCALE PET, a software that automatically analyzes amyloid-PET images that would otherwise require a time-consuming manual analysis by radiologists. Neurophet SCALE PET combines PET and MRI images to analyze Alzheimer’s disease biomarkers such as amyloid beta protein and tau protein at ultra-high sp...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Brain/ Mental Health Technology & Innovation Alzheimer’s disease treatments Alzheimers-disease anti-amyloid antibody treatments brain image analysis donanemab lecanemab microhemorrhage diagnosis Neurophet positron emission tomography Source Type: blogs